This Bexsero market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to factors such as a higher disease burden, greater demand for meningococcal vaccines, robust healthcare infrastructure, growing vaccine demand, and enhanced awareness of the disease.
The anticipated growth in the forecast period is driven by factors such as the rising prevalence of meningitis, increased research and development efforts, a stronger emphasis on preventive healthcare, expanding immunization programs, and greater vaccine acceptance among parents. Key trends in the forecast period include advancements in Medicare, government initiatives, progress in mRNA vaccine technology (with potential for MenB vaccines), innovations in vaccine development, and the creation of new vaccine delivery methods.
The rising incidence of meningitis is anticipated to drive the growth of the bexsero market in the coming years. Meningitis involves inflammation of the protective membranes surrounding the brain and spinal cord, typically caused by infection. Several factors contribute to the increasing prevalence of meningitis, including higher infection rates, changes in vaccination coverage, weakened immunity, and better detection and reporting systems. Bexsero helps protect against meningitis by stimulating the immune system to produce antibodies targeting Neisseria meningitidis group B bacteria, thus reducing the risk of invasive meningococcal disease, which can lead to life-threatening inflammation of the brain and spinal cord. For example, the UK Health Security Agency (UKHSA) reported in August 2024 that 396 cases of invasive meningococcal disease were confirmed in 2022-2023, a sharp rise from 205 cases in 2021-2022. Of these, 356 were cases of MenB invasive disease, up from 179 cases in 2021-2022 and 61 in 2020-2021. Consequently, the growing prevalence of meningitis is driving the demand for bexsero.
The expansion of research and development (R&D) activities is also expected to boost the bexsero market in the future. R&D refers to the systematic exploration of new knowledge, products, or technologies through research and experimentation. The rise in R&D activities is fueled by the increasing demand for innovative solutions to address emerging health threats and enhance treatment effectiveness. For bexsero, R&D efforts allow for the optimization of its formulation, improvement of its safety and efficacy, and expansion of its use to broader populations and emerging strains of meningococcus. In May 2024, the Office for National Statistics (ONS) reported that total net expenditure on R&D, including contributions to the EU R&D budget, reached $20.87 billion (£16.4 billion) in 2022, marking an 8.9% increase from $19.1 billion (£15 billion) in 2021. As a result, the rising investment in R&D is contributing to the growth of the bexsero market.
A key trend driving the bexsero market is the development of innovative products such as the meningococcal B vaccine, aimed at providing broader protection against various strains within serogroup B. This vaccine targets Neisseria meningitidis serogroup B, the bacterium responsible for invasive meningococcal diseases such as meningitis and bloodstream infections. In July 2024, GlaxoSmithKline (GSK) launched the Bexsero vaccine in South Korea. The vaccine contains four recombinant proteins - NHBA, NadA, fHbp, and the outer membrane vesicle PorA P1.4 - chosen based on a complete genetic analysis of meningococcal B. These components stimulate the production of bactericidal antibodies that target multiple meningococcal B antigens.
The key company operating in the bexsero market is GlaxoSmithKline plc.
North America was the largest region in the bexsero market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bexsero report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bexsero market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Bexsero is a vaccine designed to prevent invasive meningococcal disease caused by the Neisseria meningitidis group B bacteria. It provides active immunization for individuals aged 2 months and older, offering protection against meningitis and septicemia resulting from this bacterial strain.
The primary forms of bexsero are injectable suspension and pre-filled syringes. An injectable suspension is a liquid formulation containing finely dispersed drug particles suspended in a liquid, meant for injection. It is distributed through hospitals, pharmacies, and public health initiatives, and is used by people of all ages, including adults, the elderly, adolescents, and children.
The bexsero market research report is one of a series of new reports that provides bexsero market statistics, including bexsero industry global market size, regional shares, competitors with a bexsero market share, detailed bexsero market segments, market trends and opportunities, and any further data you may need to thrive in the bexsero industry. This bexsero market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The bexsero market consists of sales of meningococcal vaccines, pneumococcal vaccines, hepatitis vaccines, influenza vaccines and travel vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to factors such as a higher disease burden, greater demand for meningococcal vaccines, robust healthcare infrastructure, growing vaccine demand, and enhanced awareness of the disease.
The anticipated growth in the forecast period is driven by factors such as the rising prevalence of meningitis, increased research and development efforts, a stronger emphasis on preventive healthcare, expanding immunization programs, and greater vaccine acceptance among parents. Key trends in the forecast period include advancements in Medicare, government initiatives, progress in mRNA vaccine technology (with potential for MenB vaccines), innovations in vaccine development, and the creation of new vaccine delivery methods.
The rising incidence of meningitis is anticipated to drive the growth of the bexsero market in the coming years. Meningitis involves inflammation of the protective membranes surrounding the brain and spinal cord, typically caused by infection. Several factors contribute to the increasing prevalence of meningitis, including higher infection rates, changes in vaccination coverage, weakened immunity, and better detection and reporting systems. Bexsero helps protect against meningitis by stimulating the immune system to produce antibodies targeting Neisseria meningitidis group B bacteria, thus reducing the risk of invasive meningococcal disease, which can lead to life-threatening inflammation of the brain and spinal cord. For example, the UK Health Security Agency (UKHSA) reported in August 2024 that 396 cases of invasive meningococcal disease were confirmed in 2022-2023, a sharp rise from 205 cases in 2021-2022. Of these, 356 were cases of MenB invasive disease, up from 179 cases in 2021-2022 and 61 in 2020-2021. Consequently, the growing prevalence of meningitis is driving the demand for bexsero.
The expansion of research and development (R&D) activities is also expected to boost the bexsero market in the future. R&D refers to the systematic exploration of new knowledge, products, or technologies through research and experimentation. The rise in R&D activities is fueled by the increasing demand for innovative solutions to address emerging health threats and enhance treatment effectiveness. For bexsero, R&D efforts allow for the optimization of its formulation, improvement of its safety and efficacy, and expansion of its use to broader populations and emerging strains of meningococcus. In May 2024, the Office for National Statistics (ONS) reported that total net expenditure on R&D, including contributions to the EU R&D budget, reached $20.87 billion (£16.4 billion) in 2022, marking an 8.9% increase from $19.1 billion (£15 billion) in 2021. As a result, the rising investment in R&D is contributing to the growth of the bexsero market.
A key trend driving the bexsero market is the development of innovative products such as the meningococcal B vaccine, aimed at providing broader protection against various strains within serogroup B. This vaccine targets Neisseria meningitidis serogroup B, the bacterium responsible for invasive meningococcal diseases such as meningitis and bloodstream infections. In July 2024, GlaxoSmithKline (GSK) launched the Bexsero vaccine in South Korea. The vaccine contains four recombinant proteins - NHBA, NadA, fHbp, and the outer membrane vesicle PorA P1.4 - chosen based on a complete genetic analysis of meningococcal B. These components stimulate the production of bactericidal antibodies that target multiple meningococcal B antigens.
The key company operating in the bexsero market is GlaxoSmithKline plc.
North America was the largest region in the bexsero market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bexsero report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bexsero market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Bexsero is a vaccine designed to prevent invasive meningococcal disease caused by the Neisseria meningitidis group B bacteria. It provides active immunization for individuals aged 2 months and older, offering protection against meningitis and septicemia resulting from this bacterial strain.
The primary forms of bexsero are injectable suspension and pre-filled syringes. An injectable suspension is a liquid formulation containing finely dispersed drug particles suspended in a liquid, meant for injection. It is distributed through hospitals, pharmacies, and public health initiatives, and is used by people of all ages, including adults, the elderly, adolescents, and children.
The bexsero market research report is one of a series of new reports that provides bexsero market statistics, including bexsero industry global market size, regional shares, competitors with a bexsero market share, detailed bexsero market segments, market trends and opportunities, and any further data you may need to thrive in the bexsero industry. This bexsero market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The bexsero market consists of sales of meningococcal vaccines, pneumococcal vaccines, hepatitis vaccines, influenza vaccines and travel vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Bexsero Market Characteristics4. Bexsero Market Trends and Strategies5. Bexsero Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Bexsero Pricing Analysis & Forecasts30. Global Bexsero Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Bexsero Market32. Recent Developments in the Bexsero Market
3. Bexsero Market Biologic Drug Characteristics
6. Global Bexsero Growth Analysis and Strategic Analysis Framework
8. Bexsero Market Segmentation
9. Global Bexsero Epidemiology of Clinical Indications
10. Bexsero Market Regional and Country Analysis
11. Asia-Pacific Bexsero Market
12. China Bexsero Market
13. India Bexsero Market
14. Japan Bexsero Market
15. Australia Bexsero Market
16. South Korea Bexsero Market
17. Western Europe Bexsero Market
18. UK Bexsero Market
19. Germany Bexsero Market
20. France Bexsero Market
21. Eastern Europe Bexsero Market
22. North America Bexsero Market
23. USA Bexsero Market
24. Canada Bexsero Market
25. South America Bexsero Market
26. Middle East Bexsero Market
27. Africa Bexsero Market
28. Bexsero Market Competitive Landscape and Company Profiles
29. Global Bexsero Market Pipeline Analysis
33. Bexsero Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Bexsero Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on bexsero market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for bexsero? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bexsero market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Formulation: Injectable Suspension; Pre-Filled Syringes2) by Distribution: Hospitals; Pharmacy Stores; Public Health Programs
3) by End User: Adults; Geriatric; Adolescents; Children
Key Companies Mentioned: GlaxoSmithKline plc
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- GlaxoSmithKline plc
